

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL

OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	None	Entity Type
0001321834	Akers Bioscience	es Inc	• Corporation
Name of Issuer			C Limited Partnership
Akers Biosciences, Inc.			C
Jurisdiction of			Limited Liability Company
Incorporation/Organization	\neg		General Partnership
NEW JERSEY	<u></u>		C Business Trust
Year of Incorporation/Organiza	tion		C Other
Over Five Years Ago Within Last Five Years			
O Within Last Five Years (Specify Year)			
C Yet to Be Formed			
2. Principal Place of	Business and	Contact Int	formation
Name of Issuer			
Akers Biosciences, Inc.			
Street Address 1		Street Address 2	
201 GROVE ROAD			
City	State/Province/Country	y ZIP/Postal	Code Phone No. of Issuer
THOROFARE	NEW JERSEY	08086	(856) 848-8698
0.0.1.1.0			
3. Related Persons			
Last Name	First Name		Middle Name
Yeaton	Howard]
		St 1 1 1 2	
Street Address 1		Street Address 2	
201 Grove Road			
City	State/Province/Cou	intry	ZIP/Postal Code
Thorofare	NEW JERSEY		08086
Relationship: Exc	ecutive Officer	Director	Promoter
Clarification of Response (if Necess	sary)		
Interim Chief Financial Officer			
Last Name	First Name		Middle Name
Schreiber	Christopher		C.
Street Address 1	<u> </u>	Street Address 2	<u></u>
201 Grove Road			
City	State/Province/Cou	intry	ZIP/Postal Code

NEW JERSEY

Executive Officer

□ Director

08086

☐ Promoter

Thorofare

Relationship:

Clarification of Respon	se (if Necessary)			
Executive Chairman	f the Board of Directors; Princip	pal Executive Officer		
				-
Last Name	First Name		Middle Name	
Silverman	Joshua			
Street Address 1		Street Address 2		
201 Grove Road				
City	State/Province/O	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respon	se (if Necessary)			
				_
Last Name	First Name		Middle Name	
White	Bill		J.	
Street Address 1		Street Address 2		_
201 Grove Road				
City	State/Province/C	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respon	se (if Necessary)			
				_
Last Name	First Name		Middle Name	
Schroeder	Robert		C.	
Street Address 1		Street Address 2		
201 Grove Road				
City	State/Province/0	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	

4. Industry Group

Clarification of Response (if Necessary)

C Agriculture	Health Care	C Retailing
Banking & Financial Services	© Biotechnology	C Restaurants
C Commercial Banking	C Health Insurance C Hospitals & Physicians	
C Insurance	C Pharmaceuticals	Technology
C Investing	Other Health Care	Computers
C Investment Banking		C Telecommunications
C Pooled Investment Fund		Other Technology
Other Banking & Financial O Services		Travel
C Business Services	Manufacturing Real Estate	C Airlines & Airports
Energy	C Commercial	C Lodging & Conventions
C Coal Mining	C Construction	O Tourism & Travel Services
C Electric Utilities	C REITS & Finance	Other Travel
C Energy Conservation C Environmental Services	C Residential C Other Real Estate	C Other
C Oil & Gas	Other Real Estate	
C Other Energy		
5. Issuer Size		
O. ISSUEL SIZE Revenue Range	Aggregate Net Asset	Value Range
No Revenues		value Kange e Net Asset Value
C \$1 - \$1,000,000	C \$1 - \$5,000,00	
C \$1,000,001 - \$5,000,000	C \$5,000,001 - 5	\$25,000,000
C \$5,000,001 - \$25,000,000	C \$25,000,001 -	\$50,000,000
C \$25,000,001 - \$100,000,000	C \$50,000,001 -	\$100,000,000
Over \$100,000,000	Over \$100,00	00,000
Decline to Disclose	C Decline to Di	sclose
C Not Applicable	C Not Applicab	ole
C		
Federal Exemption(s) a apply)	and Exclusion(s) Clain	ned (Select all that
Rule 504(b)(1) (not (i), (ii)	Rule 505	
01 (III))	The same of the sa	
Rule 504 (b)(1)(i)	Rule 506(b)	
Rule 504 (b)(1)(ii)	Rule 506(c)	
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)	
	Investment Company Act Sec	tion 3(c)
7. Type of Filing		
New Notice Date of First Sale	2020-03-23	First Sale Yet to Occur
Amendment		
Amendment		
8. Duration of Offering		
8. Duration of Offering Does the Issuer intend this offering to last n	ore than one year?	O Yes O No
	nore than one year?	Yes © No
Does the Issuer intend this offering to last n		
9. Type(s) of Securities O		

Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
Minimum Investment Minimum investment accepted from any outside
investor \$ 0
12. Sales Compensation
Recipient CRD Number None
(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD None Number
Street Address 1 Street Address 2
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation All States
13. Offering and Sales Amounts
Total Offering Amount \$ 2718057 USD □ Indefinite
Total Amount Sold \$ 1233057 USD
Total Remaining to be Sold USD ☐ Indefinite
Clarification of Response (if Necessary)
Upon the achievement of certain milestones, the Company shall
issue an additional 750,000 shares of its common stock, equal to \$1,485,000 of the above listed total offering amount.
14. Investors
14. IIIVesiois
Select if securities in the offering have been or may be sold to persons who
do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold
to persons who do not qualify as accredited investors, enter the total
number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Sales Commissions	\$	USD	Estimate	
Finders' Fees	\$ 0	USD	Estimate	
Clarification of Response (if Necessar	y)			
16. Use of Proceeds				
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.				

Estimate

Signature and Submission

Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Akers Biosciences, Inc.	/s/ Howard Yeaton	Howard Yeaton	Interim Chief Financial Officer	2020-04-07